- Home
- CGC vs XOMAP Comparison
CGC vs XOMAP Comparison
Compare CGC & XOMAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CGC | XOMAP |
|---|---|---|
| Founded | N/A | N/A |
| Country | Canada | United States |
| Employees | N/A | 14 |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 404.3M | N/A |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | CGC | XOMAP |
|---|---|---|
| Price | $1.05 | $25.34 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 9.9M | 4.6K |
| Earning Date | 05-29-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 36.75 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,759,000.00 | N/A |
| Revenue This Year | $8.27 | N/A |
| Revenue Next Year | $15.68 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.84 | $25.14 |
| 52 Week High | $2.38 | $27.30 |
Technical Indicators
Market Signals| Indicator | CGC | XOMAP |
|---|---|---|
| Relative Strength Index (RSI) | 45.71 | 45.29 |
| Support Level | $1.01 | $25.22 |
| Resistance Level | $1.23 | $25.60 |
| Average True Range (ATR) | 0.05 | 0.09 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 43.61 | 43.23 |
Price Performance
Historical ComparisonAbout CGC Canopy Growth Corporation
Canopy Growth Corp, cultivates and sells medicinal and recreational cannabis and hemp through a portfolio of brands that include Doja, LivRelief, Ace Valley, Deep Space, and others. The Company is engaged in reportable segments namely: Canada cannabis, International markets cannabis, Storz & Bickel, and This Works. The company generates maximum revenue from Canadian cannabis.
About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates. The Company's drug royalty aggregator business is mainly focused on the acquisition of early to mid-stage clinical assets. Geographically, the company operates in Switzerland, the United States, Asia Pacific, Europe, and other regions.